Jefferies Downgrades Greggs Amid Evidence Weight-Loss Drugs Are Denting Footfall
Jefferies has moved Greggs to a 'hold' rating from 'buy' and lowered its price target to 1,610p, pointing to growing evidence that rapid adoption of GLP-1 weight-loss drugs is producing a persistent reduction in customer volumes. The brokerage has reduced like-for-like growth forecasts and models margin compression across FY26 and FY27, while manag…